ArticleCureus2024
Complications of Coexisting Thymoma and Myelodysplastic Syndrome: A Case Report.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A thymoma is a rare malignant tumor of the thymus gland, often associated with local invasion, recurrence, and autoimmune disorders. The interplay between thymoma and myelodysplastic syndrome (MDS) represents a complex clinical phenomenon, yet its underlying mechanisms and optimal management strategies remain incompletely understood. We present the case of a 69-year-old male with recurrent thymoma, initially classified as type B1/AB, complicated by the subsequent development of MDS. The patient, who had worked as a plumber for over 20 years, had previously undergone robotic video-assisted thoracoscopic surgery (VATS), chemotherapy, immunotherapy, radiation, and stereotactic body radiation therapy (SBRT) in an attempt to treat the thymoma. Despite these interventions, the tumor recurred, invading the left lung pleura. Following his admission to our hospital, he experienced subsequent hospitalizations for anemia, recurrent pleural effusions, and leukocytosis, which were managed with blood transfusions, thoracentesis, and antibiotics. The onset of MDS in this patient raises questions about the potential interplay between thymoma and hematologic disorders, possibly related to immunological dysregulation, genetic predisposition, occupational exposure, or environmental factors. This case illustrates the intricate link between recurrent thymoma and the onset of MDS. It emphasizes the necessity for further research to uncover their underlying mechanisms and identify novel therapeutic targets for this intriguing clinical entity. Additionally, the case reinforces the vital role of a multidisciplinary approach in treating both thymoma and MDS, as the complexities of care require collaborative efforts to ensure optimal patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.